ROCÍO
GARCÍA CARBONERO
Profesora asociada de Ciencias de la Salud
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (5)
2023
-
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
The Lancet, Vol. 402, Núm. 10395, pp. 41-53
-
Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.
Journal of Clinical Oncology
2021
-
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312
2019
-
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy
Annals of Oncology, Vol. 30, Núm. 3, pp. 439-446
2018
-
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors
Oncologist, Vol. 23, Núm. 7, pp. 766-e90